Turning the tide: pembrolizumab’s triumph in adjuvant RCC therapy
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02486-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2024. Verfasst von Fouad Attieh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Saint Joseph University of Beirut, Riad El Solh, 11-5076, Beirut, 11072180, Lebanon. fouad.attieh@net.usj.edu.lb. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
In recent years, kidney cancer has shown an increased worldwide incidence of more than 400 000 novel cases annually. Although more than half of patients are diagnosed at a localised stage, this disease presents a high-risk of relapse after surgery. Thus, there is a need for adjuvant therapy post-resection to reduce cancer recurrence and prolong disease-free and overall survival. Thorough investigation of adjuvant drugs for renal cell carcinoma (RCC) has shown little promise in the last fifty years, with no recorded overall survival benefits. This was the case until pembrolizumab, an immune checkpoint inhibitor, was introduced into the adjuvant RCC space through the KEYNOTE-564 trial. The adjuvant administration of this novel anti-PD-1 drug demonstrated a significant overall survival benefit which has led to an update in the current treatment guidelines of RCC. This substantial change in the standard of care also caused an investigation of possible treatment combinations and an adoption of innovative predictive biomarkers. In this review, we will present the evolution of past adjuvant ICI trials for the treatment of RCC, the implications of pembrolizumab's overall survival benefits and a discussion of future directions concerning new RCC drug trials and liquid biopsy-based biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Saint Joseph University of Beirut, Riad El Solh, 11-5076, Beirut, 11072180, Lebanon. fouad.attieh@net.usj.edu.lb.
- Faculty of Medicine, Saint Joseph University of Beirut, Riad El Solh, 11-5076, Beirut, 11072180, Lebanon.
- Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Riad El Solh, 11-5076, Beirut, 11072180, Lebanon.
- Oncology Department, Prince Sultan Military Medical City, Makkah Al Mukarramah Rd, As Sulimaniyah, Riyadh, 12233, Kingdom of Saudi Arabia.
- Oncology Department, Faculty of Medicine, Minia University, Minia, Egypt.
Zitieren
APA
Attieh, F., Boutros, M., Kourie, H. R., & Mahrous, M. (2024). Turning the tide: pembrolizumab’s triumph in adjuvant RCC therapy. Medical Oncology. https://doi.org/10.1007/s12032-024-02486-3
Vancouver
Attieh F, Boutros M, Kourie HR, Mahrous M. Turning the tide: pembrolizumab’s triumph in adjuvant RCC therapy. Medical Oncology. 2024. doi:10.1007/s12032-024-02486-3
BibTeX
@article{Attieh2024,
author = {Attieh, Fouad and Boutros, Marc and Kourie, Hampig Raphaël and Mahrous, Mervat},
title = {Turning the tide: pembrolizumab’s triumph in adjuvant RCC therapy},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02486-3}
}
EUVIMED